- Home
- SGA vs RPTX Comparison
SGA vs RPTX Comparison
Compare SGA & RPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGA
- RPTX
- Stock Information
- Founded
- SGA 1986
- RPTX 2016
- Country
- SGA United States
- RPTX Canada
- Employees
- SGA N/A
- RPTX N/A
- Industry
- SGA Broadcasting
- RPTX Biotechnology: Pharmaceutical Preparations
- Sector
- SGA Consumer Discretionary
- RPTX Health Care
- Exchange
- SGA Nasdaq
- RPTX Nasdaq
- Market Cap
- SGA 78.8M
- RPTX 78.2M
- IPO Year
- SGA 1992
- RPTX 2020
- Fundamental
- Price
- SGA $12.18
- RPTX $1.69
- Analyst Decision
- SGA
- RPTX Strong Buy
- Analyst Count
- SGA 0
- RPTX 3
- Target Price
- SGA N/A
- RPTX $3.50
- AVG Volume (30 Days)
- SGA 6.2K
- RPTX 209.3K
- Earning Date
- SGA 11-06-2025
- RPTX 11-07-2025
- Dividend Yield
- SGA 8.26%
- RPTX N/A
- EPS Growth
- SGA N/A
- RPTX N/A
- EPS
- SGA 0.03
- RPTX N/A
- Revenue
- SGA $109,822,000.00
- RPTX $250,000.00
- Revenue This Year
- SGA N/A
- RPTX N/A
- Revenue Next Year
- SGA $5.37
- RPTX N/A
- P/E Ratio
- SGA $415.37
- RPTX N/A
- Revenue Growth
- SGA N/A
- RPTX N/A
- 52 Week Low
- SGA $10.75
- RPTX $0.89
- 52 Week High
- SGA $14.27
- RPTX $4.07
- Technical
- Relative Strength Index (RSI)
- SGA 45.89
- RPTX 38.67
- Support Level
- SGA $11.89
- RPTX $1.75
- Resistance Level
- SGA $12.45
- RPTX $1.87
- Average True Range (ATR)
- SGA 0.30
- RPTX 0.08
- MACD
- SGA -0.02
- RPTX -0.02
- Stochastic Oscillator
- SGA 26.36
- RPTX 13.11
About SGA Saga Communications Inc. (FL)
Saga Communications Inc is a broadcast company engaged in acquiring, developing, and operating broadcast properties. The company's objective is to operate top billing radio stations in mid-sized markets. It derives a majority of its revenue from the sale of advertising for broadcast on its stations.
About RPTX Repare Therapeutics Inc.
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.